August 18, 2020Management
AGC Expands Contract with Novavax for Manufacture of Adjuvant for COVID-19 Vaccine Candidate
AGC Biologics’ global network spans three continents, with cGMP compliant facilities in Japan, the US, and Europe. It provides a wide variety of high value-added services that range from process development to manufacturing of clinical and commercial biopharmaceutical supplies. The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing its role in manufacturing COVID-19 vaccines and therapeutics in partnership with pharmaceutical companies.
Notes:
*1 CDMO: Contract Development & Manufacturing Organization. A company which is contracted or acts on behalf of another company to handle product manufacturing as well as the development of manufacturing processes.
*2 Adjuvant component: A substance used in combination to augment or enhance the effect of a vaccine
REFERENCE
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Matrix-M™ is Novavax’ proprietary saponin-based adjuvant incorporated in the vaccines developed by the company to enhance the immune response and stimulate high levels of neutralizing antibodies.
Visit the URL below for more details.
URL:www.novavax.com.
- MEDIA INQUIRIES
- Kazumi Tamaki, General Manager, Corporate Communications & Investor Relations Division
AGC Inc. - Contact: Yuki Kitano
- TEL: +81-3-3218-5603
- E-mail: info-pr@agc.com